Please note that for any DOS on or after 7/3/26, MA Medicaid will no longer cover the following drugs for weight loss and obesity indication. The updated coverage will apply MA UHC Community Health Plan.

---

What is not changing?

The drugs are still covered for indications that are covered by CMS: type 2 diabetes, obstructive apnea and cardiovascular disease.

---

The following drugs are affected:

• Contrave® (naltrexone/bupropion)
• Didrex (benzphetamine)
• Dietylpropion (diethylpropion extended release)
• Lomaira®, Adipex-P® (phentermine capsule, tablet)
• Mounjaro® (tirzepatide)
• Ozempic® (semaglutide)

• Phendimetrizine (phendimetrazine extended release)
• Qsymia® (phentermine/topiramate)
• Saxenda® (liraglutide)
• Wegovy® (semaglutide)
• Xenical® (orlistat) 
• Zepbound® (tirzepatide)

---

If are a provider that accepts UHC MA community health mwmbers in your office and has any of the CMS covered DXs and no auth, please click here to request one.

---

Find this information useful? Follow my blog fpr more!

---

Need a medical coding/billing/reimbursement guide? Click here for CART-T.

---

• NY UHC Community Plan- no payment for 97161-97168 codes
• NM UHC Community plan- avoiding costly denials
• FidelisCare: pre- pay claim review for COB – third party payers
• Tobacco screening services- proper coding and billing- UPMC Community Behavioral Health Org:UPMC Community Behavioral Health Org
• Are you using the proper Anesthesia codes for fascial plane blocks?